Hyponatremia
ICD-10 E87.1 · ICD-11 5C72

Treatment of Chronic Hyponatraemia in Liver Cirrhosis or Heart Failure Without Severe Symptoms

This protocol addresses patients with chronic hyponatraemia — documented to exist for at least 48 hours — presenting with serum sodium below 135 mmol/l, expanded extracellular fluid volume (as seen in liver cirrhosis or heart failure), and without severe or moderately severe symptoms.

Clinical Scenario

The defining features are a documented chronicity of at least 48 hours, low serum sodium, and a volume-expanded state driven by an underlying condition such as liver cirrhosis or heart failure. The absence of severe or moderately severe symptoms places this presentation in a specific management category where the rationale for sodium correction differs from acute or symptomatic hyponatraemia.

Management Approach (Overview)

The approach centres on addressing the underlying cause and eliminating contributing factors, rather than targeting serum sodium correction as a primary goal in its own right. Fluid management plays a key role. Specific pharmacological agents are actively recommended against in this setting. The complete, structured regimen — including the full sequence of interventions — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

  1. We define 'chronic' hyponatraemia as hyponatraemia that is documented to exist for at least 48 h.
  2. There are insufficient data to suggest that increasing serum sodium concentration improves patient-important outcomes in moderate hyponatraemia with expanded extracellular fluid volume, such as seen in liver cirrhosis or heart failure.
  3. We recommend cause-specific treatment (1D).
  4. We suggest fluid restriction to prevent further fluid overload (2D).
  5. We recommend against vasopressin receptor antagonists (1C).
  6. We recommend against demeclocycline (1D).
View source ↗